[1] 汤晓涵, 李 霞, 周智广. 成人隐匿性自身免疫糖尿病:已知与未知[J]. 中华糖尿病杂志, 2021,13(4):442-445.
[2] 中国医师协会内分泌代谢科医师分会, 国家代谢性疾病临床医学研究中心. 成人隐匿性自身免疫糖尿病诊疗中国专家共识(2021版)[J]. 中华医学杂志, 2021,101(38):3077-3091.
[3] 周智广, 纪立农, 陆菊明. 中华医学会糖尿病学分会关于成人隐匿性自身免疫糖尿病(LADA)诊疗的共识[J]. 中华糖尿病杂志, 2012,4(11):641-647.
[4] Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel[J]. Diabetes, 2020,69(10):2037-2047.
[5] Zhang Z, Yan X, Wu C, et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: a 1-year pilot study[J]. Diabetes Metab Res Rev, 2020,36(5):e3298.
[6] Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus[J]. Ann N Y Acad Sci, 2002,958:117-130.
[7] Fadiga L, Saraiva J, Catarino D, et al. Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation[J]. Diabetol Metab Syndr, 2020,12(1):107.
[8] Hawa M I, Buchan A P, Ola T, et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes[J]. Diabetes Care, 2014,37(6):1643-1649.
[9] 纪立农, 郭立新, 郭晓蕙, 等. 钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议[J]. 糖尿病天地(临床), 2016,10(12):544-548.
[10] Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives[J]. Diabetes Metab Res Rev, 2017,33(5): .
[11] Hamblin P S, Wong R, Ekinci E I, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission[J]. J Clin Endocrinol Metab, 2019,104(8):3077-3087.
[12] Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors[J]. J Diabetes Investig, 2016,7(2):135-138.